Showing results 1 to 1 of 1
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong Journal:Cost Effectiveness and Resource Allocation | 2020 | 83 |